CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. NTGN, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O'Dowd, Chief Executive Officer of Neon, will present at the Jefferies 2019 Healthcare Conference on Friday, June 7, 2019 at 12:30 p.m. ET.
A live webcast of the presentation will be available by visiting the Investors section of Neon Therapeutics' website at ir.neontherapeutics.com. A replay of the webcast will be archived on the Neon Therapeutics website for 30 days following the presentation.
About Neon Therapeutics
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical-stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of hormone receptor-positive (HR+) breast cancer.
For more information, please visit www.neontherapeutics.com.
Investor Contact:
Paul Cox, Corporate Affairs and Strategy
pcox@neontherapeutics.com
617-337-4762
Media Contact:
Stephanie Simon, Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.